bemcentinib + cytarabine

Bemcentinib + cytarabine is a **combination therapy** investigated predominantly for the treatment of **acute myeloid leukemia (AML)** in patients unfit for intensive chemotherapy, especially those with relapsed/refractory (R/R) disease or newly diagnosed but vulnerable due to age or co-morbidities. Bemcentinib is a potent, highly selective, orally bioavailable **AXL receptor tyrosine kinase inhibitor**. AXL is implicated in poor AML prognosis, chemotherapy resistance, and dampening antitumor immune response. Cytarabine is a well-established antimetabolite chemotherapeutic that inhibits DNA synthesis. The combination leverages bemcentinib’s ability to sensitize leukemic cells (by targeting AXL-related pathways of resistance and immune evasion) with the cytotoxic antileukemic activity of cytarabine[1][3][4][5][7]. The combination has been tested at low doses of cytarabine, primarily for improved safety and tolerability in older or comorbid patients.

Other names

bemcentinib + low-dose cytarabineBEM + LDAC